Korro Bio, Inc. — 2023 Form 10-K
Reporting period: Fiscal year ended December 31, 2023. The filing was signed March 26, 2024. Korro is a clinical-stage-in-waiting biopharmaceutical company developing RNA-editing medicines; it has no approved products, product sales, or clinical trials underway.
Business context and reporting basis
On November 3, 2023, Frequency Therapeutics completed its business combination with Legacy Korro, and Frequency changed its name to Korro Bio. The merger was accounted for as a reverse recapitalization, with Legacy Korro as the accounting acquirer; the reported financial statements therefore principally reflect Legacy Korro’s historical operations. The merger and related financing substantially changed the company’s capital structure and cash position, so year-over-year comparisons should be read in that context.
Financial performance and liquidity
| Metric | 2023 | 2022 |
|---|---|---|
| Revenue from product sales | None | None |
| Research and development expense | $57.3 million | $42.2 million |
| General and administrative expense | $27.3 million | $16.8 million |
| Total operating expenses | $84.5 million | $59.0 million |
| Other income, net | $3.4 million | $1.0 million |
| Net loss | $81.2 million | $58.0 million |
| Net cash used in operating activities | $67.3 million | $53.6 million |
Operating expenses increased $25.5 million year over year. R&D growth reflected higher external research, staffing and facilities costs, partly offset by lower lab supplies; G&A growth included merger-related severance, professional services and facility costs. The filing reports no gross margin or product revenue from which to assess operating margins.
At year-end, cash and cash equivalents were $166.2 million; restricted cash was $7.0 million, bringing cash, cash equivalents and restricted cash to $173.1 million. Current assets were $172.7 million and current liabilities $19.5 million. Total liabilities were $51.8 million, including $33.2 million of operating lease liabilities; the filing does not report borrowings or other financial debt.
Net cash provided by financing activities was $187.8 million, principally reflecting $117.3 million from the pre-closing financing, $45.5 million net proceeds from Series B-2 preferred stock and $36.6 million of cash acquired in the merger, partly offset by $12.2 million of merger transaction costs. Investing activities provided $11.2 million, mainly from investment maturities, offset by capital expenditures.
Material changes, outlook and key risks
- Management estimated that year-end cash and cash equivalents would fund operating and capital needs into 2026. The financial-statement note states funding for at least 12 months from issuance. Management cautions that runway depends on assumptions and may be shorter; additional financing may be required.
- KRRO-110, the lead candidate for alpha-1 antitrypsin deficiency (AATD), was nominated in December 2023. The company targeted a potential regulatory filing in the second half of 2024 and an interim clinical readout in the second half of 2025. These were plans, not achieved milestones; no IND had been submitted and no human clinical data existed as of the filing.
- Other programs—including Parkinson’s disease, severe alcohol-associated hepatitis, ALS, pain and cardiometabolic disease—remained in research or preclinical development. The company emphasized that RNA editing is novel and clinically unvalidated, with uncertain human safety, efficacy, delivery and regulatory requirements. LNP delivery for RNA editing had not been clinically proven, and the KRRO-110 delivery system was not finalized.
- Genevant agreement obligations include reimbursement of certain costs, potential clinical milestones up to $13.5 million, regulatory and development milestones up to $27.0 million, commercial milestones up to $57.0 million, and mid-single-digit royalties on eligible future net sales. No milestones had been achieved by year-end.
- The former Frequency multiple-sclerosis assets were transferred to Progentos. The agreement includes potential milestone payments up to $17.5 million and a conditional $0.7 million payment. Related contingent arrangements were valued using significant unobservable assumptions; the CVR liability and asset were each reported at approximately $1.4 million at year-end.
- A securities class action concerning former Frequency disclosures remains on appeal after dismissal; the First Circuit heard oral argument in January 2024 and had not ruled. The company could not estimate a possible loss and recorded no accrual.
- The company disclosed that management did not assess internal control over financial reporting for 2023, primarily because of the merger and resulting changes; it planned its initial assessment as of December 31, 2024. Management concluded disclosure controls and procedures were effective at year-end. The auditor issued an unqualified opinion on the financial statements but did not audit internal-control effectiveness.
Most important facts for investors to verify
- Whether KRRO-110’s regulatory filing and clinical-readout timelines remain achievable, and what FDA feedback or additional studies are required.
- Updated cash burn, committed spending and financing needs relative to management’s runway estimate; distinguish unrestricted cash from restricted cash.
- Whether preclinical editing, safety and delivery results translate to human clinical benefit, especially given the platform’s lack of clinical validation.
- The terms, timing and potential financial impact of Genevant milestones and royalties, the Progentos contingent payments, and the CVR arrangements.
- The outcome of the Frequency securities-litigation appeal and any subsequent estimate or accrual of potential loss.
- Progress on internal-control assessment and any identified material weaknesses, as well as the effect of merger-related and public-company costs on future expenses.